Xinnuowei: Announcement of Resolutions of the First Extraordinary Shareholders Meeting in 2026
Securities code: 300765 Securities abbreviation: Xinnuowei Announcement number: 2026-011
CSPC Innovative Pharmaceutical Co., Ltd.
Announcement of Resolutions of the First Extraordinary Shareholders Meeting in 2026
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Special tips:
No resolution was vetoed at this shareholders’ meeting.
This shareholders’ meeting does not involve changes to the resolutions passed by previous shareholders’ meetings.
1. Meeting convening and attendance
The session of the shareholders’ meeting: the first extraordinary shareholders’ meeting in 2026.
Convener of the meeting: the company’s board of directors.
Meeting host: Yao Bing, chairman of the company.
Date and time of the meeting:
(1) On-site meeting time: Starting at 14:30 pm on February 24, 2026 (Tuesday). (2) Online voting time: The specific time for online voting through the Shenzhen Stock Exchange trading system is: February 24, 2026 9:15-9:25, 9:30-11:30, 13:00-15:00; the specific time for voting through the Shenzhen Stock Exchange Internet voting system is: February 24, 2026 9:15-15:00.
The on-site meeting will be held at: Company Conference Room, No. 896, Zhongshan East Road, High-tech Zone, Shijiazhuang City, Hebei Province.
Number of shareholders attending the meeting:
There were 381 shareholders voting on site and online, representing 116,520,295 shares, accounting for 8.3671% of the company's total voting shares.
Among them: No shareholders or shareholders’ authorized representatives attended the shareholders’ meeting on site. There were 381 shareholders voting online, representing 116,520,295 shares, accounting for 8.3671% of the company's total voting shares.
This meeting complied with the relevant provisions of the "Company Law of the People's Republic of China", the "Shenzhen Stock Exchange GEM Stock Listing Rules" and the "Articles of Association", and the meeting was legal and valid. The company's directors, senior managers and lawyers from Beijing Hairun Tianrui Law Firm attended and attended the shareholders' meeting. Beijing Hairun Tianrui Law Firm appointed a lawyer to witness this meeting and issued a legal opinion.
2. Proposal review and voting status
No shareholders or shareholders’ authorized representatives were present at this shareholders’ meeting. Therefore, there was no on-site voting method. Shareholders attending the meeting voted through online voting. The following proposals were reviewed and approved at the meeting:
Proposal 1.00 "Proposal on the signing of strategic cooperation and authorization agreements and related transactions between controlled subsidiaries and related parties with AstraZeneca"
Voting results:
116,152,510 shares were approved, accounting for 99.6844% of the total number of shares with valid voting rights present at this shareholders' meeting; 98,485 shares were opposed, accounting for 0.0845% of the total number of shares with valid voting rights present at this shareholders' meeting; 269,300 shares were abstained (of which 0 shares were abstained by default due to non-voting), accounting for 0.2311% of the total number of shares with valid voting rights present at this shareholders' meeting.
Among them, the voting results of small and medium shareholders are:
116,152,510 shares were approved, accounting for 99.6844% of the total number of shares with valid voting rights of small and medium-sized shareholders attending this shareholders' meeting; 98,485 shares were opposed, accounting for 0.0845% of the total number of shares with valid voting rights of small and medium-sized shareholders attending this shareholders' meeting; 269,300 abstained shares (of which 0 shares abstained by default due to non-voting), accounting for 0.2311% of the total number of shares with valid voting rights for small and medium-sized shareholders attending this shareholders’ meeting.
Related party shareholders CSPC Enbipu Pharmaceutical Co., Ltd. and CSPC Ouyi Pharmaceutical Co., Ltd., the related party shareholders of this resolution, abstained from voting and were voted by non-related party shareholders and passed.
3. Legal opinions issued by lawyers
This shareholders' meeting was witnessed by a lawyer appointed by Beijing Hairun Tianrui Law Firm and a legal opinion was issued. It was held that: the convening and convening procedures of the company's first extraordinary shareholders' meeting in 2026 complied with the provisions of the "Company Law", the Rules of Shareholders' Meetings of Listed Companies and the "Articles of Association"; the qualifications of the personnel attending this shareholders' meeting and the qualifications of the convener complied with the provisions of the "Company Law", the Rules of Shareholders' Meetings of Listed Companies and the "Articles of Association"; the voting procedures and results of this shareholders' meeting were legal and valid.
4. Documents for reference
"Resolution of the First Extraordinary Shareholders Meeting of CSPC Pharmaceutical Co., Ltd. in 2026";
"Legal Opinion of Beijing Hairun Tianrui Law Firm on the First Extraordinary Shareholders Meeting of CSPC Pharmaceutical Co., Ltd. in 2026".
Announcement is hereby made.
Board of Directors of CSPC Innovation Pharmaceutical Co., Ltd.
February 24, 2026